Form 4: Beam Therapeutics Executive Sells Shares for Tax Withholding

Giuseppe Ciaramella, President at Beam Therapeutics, sold 11,810 shares of common stock on April 1, 2026, to cover tax withholding obligations related to vested restricted stock units.

Summary

• Giuseppe Ciaramella, President of Beam Therapeutics Inc., engaged in a transaction involving the sale of 11,810 shares of common stock on April 1, 2026.
• The sale was executed at a price of $24.58 per share, resulting in a total transaction value of approximately $289,993.80.
• These shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units.
• The restricted stock units were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on various dates between March 31, 2022, and March 31, 2025.
• The transaction was conducted under a Rule 10b5-1 trading plan, adopted by Mr. Ciaramella on May 23, 2023, which is designed to satisfy affirmative defense conditions for insider trading.
• Following this transaction, Mr. Ciaramella beneficially owns 218,406 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a routine transaction for tax purposes under a pre-arranged plan and does not necessarily reflect a negative view of the company's prospects by the executive.

Future Outlook

The transaction was executed under a pre-established Rule 10b5-1 trading plan, indicating a pre-determined strategy for managing equity holdings and tax obligations.

Industry Context

StockSavvy.ai notes that executive stock sales for tax withholding are a common and expected event, particularly following the vesting of equity awards. The use of a Rule 10b5-1 plan further suggests a structured approach to managing these obligations, which is generally viewed favorably by the market as it mitigates concerns about opportunistic insider trading.

Stakeholder Impact

• Shareholders: The sale is a routine event for tax withholding and is executed under a 10b5-1 plan, thus unlikely to have a significant negative impact on share price or investor sentiment.

Key Dates

Keywords

Form 4, SEC Filing, Beam Therapeutics, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Executive Compensation